Also found in: Medical.
SEROCOSears Roebuck Company
References in periodicals archive ?
Belanger F, Meyer L, Carre N, Coutellier A, Deveau C- Influence of age at infection on human immunodeficiency virus disease progression to different clinical endpoints: the SEROCO cohort (1988-1994).
A study of the French PRIMO and SEROCO cohorts recorded no long-term CD4 benefit in 170 people who started antiretrovirals within 3 months of infection--then suspended therapy--compared with 123 people who did not begin treatment.
Belanger F, Derouin F, Grangeot-Keros L, Meyer L; HEMOCO and SEROCO Study Groups.